ArtVentive Medical Group, Inc. (“ArtVentive”) announced today that it filed a Form 15 with the Securities and Exchange Commission relieving it of all reporting requirements with the Securities and Exchange Commission.
The ArtVentive team conducted a series of very successful meetings and workshops at the conference with EOS™ which was featured in several prominent events held at the conference auditorium, the exhibition floor and at hands-on workshops.
EOS™ attracted considerable attention from the audience, primarily interventional radiologists from the US, Europe, Australia and Asia, because it is the only occlusion device that immediately, safely and accurately stops blood flow.
ArtVentive EOS™ Device featured at SIR 2017 Conference
Visit us at booth #560.
ArtVentive Medical Group, Inc. (“ArtVentive”) announced today its strategic sales plan for the company’s growth and highlighted recent commercialization progress in the United States and Europe.
Dr, Leon Rudakov, ArtVentive’s founder and Chief Technology Officer, and Bill Olson, newly appointed Chief Executive Officer, identified an innovative sales and marketing strategy for ArtVentive’s revolutionary blood vessel occlusion device EOS™.
Successful embolization procedures with ArtVentive EOS™. This study aimed to collect confirmatory data in support of the safety and efficiency of the ArtVentive EOS™ for the treatment of the pelvic congestion syndrome (PCS). A decrease in pelvic pain intensity based on the VAS was considered a clinical success.
ArtVentive Medical Group, Inc. commenced the launch of its flagship occlusion device product, the ArtVentive Endoluminal Occlusion System (EOS™) at the Global Embolization Symposium and Technologies (GEST) in New York, NY on May 5-8. The introduction in the United States follows the initial commercialization in the E.U. last year.
Join us at the ArtVentive Booth #28 to learn more about the EOS™ Endoluminal Occlusion System at the GEST 2016 U.S. conference in New York.
Conference Dates: 05/05/16 – 05/08/16.
Adrian Moelker, MD, PhD, a radiologist at the Erasmus MC-University Medical Centre in the Netherlands, will present his poster abstract on the ArtVentive EOS™ Device at the GEST 2016 U.S. conference in New York conference in May
Occlusion of blood vessels with the use of endovascular techniques is a fundamental concept for interventional management of urgent and emergent vascular conditions (1,2). However, complete and durable vessel occlusion is difficult to achieve with the currently available mechanical devices, most common among which are coils or plugs. The endoluminal occlusion system (EOS; ArtVentive, Carlsbad, California) is a family of catheter-based, expandable endoluminal mechanical occlusion devices. The possible clinical indications of the EOS device include management of venous (eg, varicocele, ovarian varices, varicose veins) and arterial (eg, emergency arterial embolization in trauma patients) conditions. As no late imaging was obtained in the present case, durable occlusion with the EOS device could be assessed in future studies.
To conclude, the EOS may provide a safe and reliable method of immediate vessel occlusion in the peripheral arterial circulation.